Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market Demand And Growth Analysis 2022-28

According to Precision Business Insights' (PBI), latest report, the Europe bruton tyrosine kinase (btk) inhibitors market size was valued at USD 1,911.3 million in 2021 and is poised to grow at a significant CAGR of 21.3% during the forecast period 2022-28. The Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market is segmented into the following types: By Molecule (Ibrutinib, Zanubrutinib, acalabrutinib, and Pirtobrutinib), Disease (Chronic lymphocytic leukemia (CLL), Diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Graft-versus-host disease (GvHD), Marginal Zone Lymphoma (MZL), Waldenström Macroglobulinemia (WM), Central nervous system lymphoma (CNSL), and Mantle cell lymphoma (MCL)), Country (Germany, United Kingdom, France, Spain, Italy), and Forecast To 2028. Increased pervasiveness of the different types of Lymphoma and Leukemia globally along with the advancement of research & innovation is the major driving force for the Bruton Tyrosine Kinase (BTK) Inhibitors treatment market to expand the prediction period.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/europe-bruton-tyrosine-kinase-inhibitors-market/

Acalabrutinib and Zanubrutinib Dominates the Market:
As it is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and activity, BTK is a potential therapeutic target for various B cell malignancies and inflammatory diseases. Five small-molecule inhibitors with excellent efficacy have been approved to treat distinct types of hematological malignancies: Ibrutinib, Acalabrutinib, Zanubrutinib, Tirabrutinib, and Orelabrutinib. A revolutionary drug called ibrutinib has made chemotherapy-free B cell cancer treatment possible once again. Ibrutinib is so well-liked that, among all cancer drugs marketed globally in 2021, it climbed to fourth position (USD 1,835.98 million in Sales). Both molecules of Acalabrutinib and Zanubrutinib account to hold more than x% by 2025 owing to their benefits associated when compared with ibrutinib. By 2025, Zanubrutinib is anticipated to hold a share of x% of the total Europe BTK inhibitors market. However, ibrutinib holds the highest share in Europe with x% followed by Acalabrutinib with x% market share. Acalabrutinib has a first-mover advantage in the 2nd generation of BTK inhibitors and focuses mainly on the CLL market.

Germany to Dominate the Bruton Tyrosine Kinase (BTK) Inhibitors Market
In terms of revenue, Germany is the largest market for Bruton Tyrosine Kinase (BTK) Inhibitors treatments in 2021, followed by the United Kingdom. Due to the increased prevalence of Chronic Lymphocytic Leukemia (CLL), Diffuse Large B Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL), Germany is predicted to have the highest growth in the sales of BTK inhibitors. The German BTK Inhibitors Market is projected to reach USD x million by 2028 owing to the launch of new molecules such as zanubrutinib, acalabrutinib, and pirtobrutinib in Germany in various indications like DLBCL, FL, MZL, CNSL, and others. For instance, in 2024, ibrutinib is expected to be launched in DLBCL patients in European countries. From 2025, this launch will improvise the sales of ibrutinib as DLBCL prevalence is x in Germany.

In 2021, with respect to the prevalence of chronic lymphocytic leukemia (CLL) diffuse large B cell lymphoma (DLBCL), and follicular lymphoma (FL), the United Kingdom is the second most promising market after Germany. the UK market is projected to grow at double-digit growth rates over the forecast period owing to the large patient population pool and the entry of new molecules into the market. For instance, in 2021, acalabrutinib was launched for CLL patients and in 2022, zanubrutinib was approved for WM patients which are anticipated to increase the growth of the BTK inhibitors market over the forecast period. However, the launch of the second-generation BTK inhibitors in France will increase the adoption of the number of patients on BTK inhibitors along with that it is also estimated that reversible BTK inhibitors undergoing clinical trials and are expected to be approved in the future.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=64999

The europe bruton tyrosine kinase (btk) inhibitors market is segmented based on molecule, disease, and country:
Based On the Molecule:
• Ibrutinib
• Zanubrutinib
• Acalabrutinib
• Pirtobrutinib

Based On Disease:
• Chronic lymphocytic leukemia (CLL)
• Diffuse large B cell lymphoma (DLBCL)
• Follicular lymphoma (FL)
• Graft-versus-host disease (GvHD)
• Marginal Zone Lymphoma (MZL)
• Waldenström Macroglobulinemia (WM)
• Central nervous system lymphoma (CNSL)
• Mantle cell lymphoma (MCL)

Based On Country:
• Germany
• United Kingdom
• France
• Spain
• Italy

The europe bruton tyrosine kinase (btk) inhibitors market key players are BeiGene, Eli Lilly and Company, Merck KGaA, Novartis AG, Sanofi, AbbVie Inc, AstraZeneca, Janssen Global Services, LLC, ONO Pharmaceutical Co., Ltd.

Contact:
Mr. Satya
Precision Business Insights | Toll-Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.